CH512469A - N-Allylpiperidine derivs. (I) R1 = H,Me R2 = H, Cl, Br, Me R3 = H, F, Cl, Br, Me R4 = H, Cl, Br, Me R5 = H, alpha- or beta - Me - Google Patents

N-Allylpiperidine derivs. (I) R1 = H,Me R2 = H, Cl, Br, Me R3 = H, F, Cl, Br, Me R4 = H, Cl, Br, Me R5 = H, alpha- or beta - Me

Info

Publication number
CH512469A
CH512469A CH1748267A CH1748267A CH512469A CH 512469 A CH512469 A CH 512469A CH 1748267 A CH1748267 A CH 1748267A CH 1748267 A CH1748267 A CH 1748267A CH 512469 A CH512469 A CH 512469A
Authority
CH
Switzerland
Prior art keywords
methyl
hydrogen
chlorine
bromine
formula
Prior art date
Application number
CH1748267A
Other languages
German (de)
Inventor
Kurt Dr Freter
Herbert Dr Merz
Hans-D Dr Schroeder
Karl Dr Zeile
Original Assignee
Boehringer Sohn Ingelheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Sohn Ingelheim filed Critical Boehringer Sohn Ingelheim
Publication of CH512469A publication Critical patent/CH512469A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

N-Allylpiperidine derivs. (I) R1 = H,Me R2 = H, Cl, Br, Me R3 = H, F, Cl, Br, Me R4 = H, Cl, Br, Me R5 = H, alpha- or beta - Me R6 = H, Cl, Me R7 = H, F, Cl, Br, Me, HO, MeO, AcO R8 = Me, Et, Pr, MeO, EtO, PrO at least 1 of R2, R3 and R4 = halogen or Me Including stereoisomers, together with nontoxic acid addn. salts and pharmaceutical compns. containing the above. Morphine antagonists and non-habit-forming analgesics. With some of the compds., this latter effect can be shown in exptl. animals.

Description

  

  
 



  Verfahren zur Herstellung von neuen Halogenallyl-piperidinen
Die Erfindung betrifft ein Verfahren zur Herstellung von Piperidinderivaten der Formel I
EMI1.1     
 worin   Rt    Wasserstoff oder Methyl,   R3    Wasserstoff, Methyl, Chlor oder Brom,    R3    Wasserstoff, Methyl, Fluor, Chlor oder   Brom,   
R4 Wasserstoff, Methyl, Chlor oder Brom,    Rr    Wasserstoff oder Methyl   (a    oder   p)       R6    Wasserstoff, Methyl oder Chlor,    R7    Methyl, Hydroxy, Methoxy, Acetoxy, Fluor, Chlor oder Brom,    Rb    Methyl, Äthyl oder Propyl bedeuten, wobei jedoch mindestens einer der Reste   R..,    R3 oder R4 ein Halogenatom bedeuten muss,

   sowie von deren Säureadditionssalzen.



   Erfindungsgemäss werden diese Verbindungen durch Umsetzung eines   Di.(-halogenäthyl)-amins    der Formel II
EMI1.2     
 worin Hal ein Halogenatom bedeutet, mit einem Benzylcyanid der Formel III
EMI1.3     
  und anschliessende Grignardierung der so erhaltenen Cyanoverbindungen der Formel IV
EMI2.1     
 und Hydrolyse der erhaltenen Ketiminverbindungen in die Ketoverbindungen der Formel I hergestellt.



   Der Ringschluss vollzieht sich in Gegenwart eines geeigneten Kondensationsmittels, wie gepulvertem Natriumamid, in einem indifferenten organischen Lösungsmittel, z.B. Toluol. Die Reaktionstemperatur liegt im allgemeinen zwischen 40 und 2000C. Man erhält so die Cyanoverbindung der Formel IV.



   Eine in einem erfindungsgemäss erhaltenen Produkt der Formel I vorhandene Hydroxylgruppe kann gegebenenfalls methyliert bzw. acetyliert werden. Umgekehrt ist es auch möglich, eine am Phenylring befindliche Methoxygruppe zu entmethylieren bzw. eine Acetylgruppe zu verseifen.



   Soll in dem Endprodukt für den Rest R7 eine Hydroxygruppe stehen, ist es im allgemeinen erforderlich, diese vor Beginn der Ringschlussreaktion durch Acylierung oder Alkylierung zu schützen. Die Entacylierung einer so geschützten Hydroxygruppe erfolgt automatisch bei der Hydrolyse der Ketiminverbindung. Befindet sich am Phenylring der Cyanocerbindung IV eine durch einen Alkylrest geschützte Hydroxygruppe, so ist es von Vorteil, die Hydrolyse der Ketiminverbindung unter Verwendung von Brom- oder Jodwasserstoffsäure durchzuführen, da hierbei zugleich der Alkylrest abgespalten wird.



   Gewünschtenfalls kann eine Verbindung der Formel I in ein physiologisch unbedenkliches Säureadditionssalz umgewandelt werden, z.B. durch Behandlung mit einer anorganischen oder organischen Säure, wie Mineralsäu   ren.    Essigsäure, Methansulfonsäure, Weinsäure, Fumarsäure, Maleinsäure, Zitronensäure, Ascorbinsäure, Capronsäure oder Propionsäure.



   Die neuen Piperidinderivate zeichnen sich durch eine ausserordentlich starke morphinantagonistische Wirkung aus: einige der Verbindungen besitzen darüber hinaus eine ausgeprägte analgetische Wirkung. Die neuen Substanzen können daher in der Humanmedizin als nichtsuchtmachende Analgetika bzw. als Zusätze zu suchtmachenden Analgetika, beispielsweise Morphin, Pethidin oder Ketobemidon, Verwendung finden. Sie lassen sich zu allen für pharmazeutische Zwecke üblichen Zubereitungsformen verarbeiten. Zum Beispiel kann man daraus Pillen, Dragees, Tabletten, Suppositorien, Emulsionen, Lösungen und Injektionslösungen herstellen.



   Beispiel trans-l   3-Chlorallyl)-i-(3-hydroxyphen.'.l)-4-cwetyl-       -piperidin -hydrochlorid   
25 g (0,074 Mol)   trans- 1 -(3 -Chlorallyl) -4-(3-me-      thoxyphenyl)-4.cyano.piperidin-hydrochlorid    werden mit 100 ml Wasser, 37 ml 2n Natronlauge und 75 ml Benzol geschüttelt, die Benzolschicht abgetrennt und die wässrige Lösung noch zweimal mit je 75 ml Benzol ausgeschüttelt. Die Benzollösungen werden vereinigt, mit   Na2SOg    getrocknet und das Benzol im Vakuum verdampft. Der Rückstand wird in absolutem Benzol gelöst, die Lösung nochmals zur Trockne verdampft, der Rückstand wieder in 50 ml absolutem Benzol gelöst und diese Lösung in eine   Grignardlösung,    bestehend aus Methylmagnesiumjodid in Benzol, von 450C eingetropft.

  Man destilliert von der Reaktionsmischung unter Rühren soviel Lösungsmittel ab, bis die Innentemperatur auf 760C gestiegen ist und rührt dann bei dieser Temperatur 16 Stunden. Anschliessend wird das Reaktionsgemisch auf 200 g Eis und 50 g Ammoniumchlorid gegossen und nach Erwärmen auf 300C dreimal mit je 200 ml Benzol extrahiert. Die vereinigten Benzollösungen werden getrocknet und das Lösungsmittel verdampft. Es hinterbleibt als Rückstand das Ketimin, welches ohne Reinigung weiter verarbeitet wird.



   Nach Zugabe von 50 g Phenol und 220 ml 48%iger HBr wird 4 Stunden unter Rückfluss gekocht, abgekühlt, mit 220 ml Wasser verdünnt und zweimal mit je 100 ml Äther ausgeschüttelt. Die Ätherlösungen werden mit 50   ml    Wasser gewaschen. Die vereinigten wässrigen Lösungen werden mit 100 ml Äther ausgeschüttelt und dann im Vakuum zur Trockne verdampft. Es hinterbleibt ein Rückstand von 5 g, der beim Lösen in wenig Alkohol und Ansäuern mit alkoholischer HCI als Hydrochlorid kristallisiert. Die Ausbeute beträgt 7,4 g (30,5% der Theorie) vom F = 1840C (aus Äthanol/Äther).



   Das als Ausgangssubstanz verwendete trans-N-(3 -Chlorallyl) - bis - (2- chloräthyl)-amin-hydrochlorid kann folgendermassen erhalten werden: a)   trans-N-(3-Chlorallyl)-diäthanolamin   
36,8 g (0,35 Mol) Diäthanolamin,   42,5 g    (0,385 Mol)   trans-1,3-Dichlorpropen    und 44 g (0,525 Mol) Natriumbicarbonat werden in 43 ml Dimethylformamid u. 107 ml Tetrahydrofuran 3 Stunden unter Rückfluss gekocht. Anschliessend wird das Lösungsmittel im Vakuum eingedampft und der Rückstand mit 100 ml Wasser und 75   ml    Chloroform geschüttelt.

  Nach Abtrennen im Scheidetrichter wird noch mehrmals mit je 50 ml Chloroform ausgeschüttelt, die vereinigten Chloroformlösungen mit    Na2SO    getrocknet und nach dem Abdestillieren des Lö    sunesmittels    die Verbindung im Vakuum destilliert. Man erhält nach 6 g Vorlauf 55,5 g (88% der Theorie) trans  -N-(3-Chlorallyl)-diäthanolamin vom   Kp0.4    = 134 bis
1360C.

 

     b) trans-N-(3 -Chlorallyl)-bis- (2-chloräthyl)-amin-hydro -    chlorid
46 g (0,256 Mol) trans-N-(3-Chlorallyl)-diäthanolamin,    anlöst    in 50 ml absolutem Chloroform, werden innerhalb von 30 Minuten unter Eiskühlung und Rühren mit 130 g
Thionylchlorid (1,1 Mol) in 100 ml Chloroform versetzt.  



  Anschliessend wird 1 Stunde unter Rückfluss gekocht, abgekühlt und mit 300 ml absolutem Äther versetzt. Das beim Stehen im Kühlschrank kristallisierte Hydrochlorid des   trans.N.(3-Chlorallyl)-bis-(2-chloräthyl)-amins    wird abgesaugt und mit Äther gewaschen. Nach dem Trocknen im Vakuum erhält man 64 g (100% der Theorie) der genannten Verbindung vom F = 620C (aus Alkohol/ Äther). 



  
 



  Process for the preparation of new haloallyl piperidines
The invention relates to a process for the preparation of piperidine derivatives of the formula I.
EMI1.1
 where Rt is hydrogen or methyl, R3 is hydrogen, methyl, chlorine or bromine, R3 is hydrogen, methyl, fluorine, chlorine or bromine,
R4 is hydrogen, methyl, chlorine or bromine, Rr is hydrogen or methyl (a or p), R6 is hydrogen, methyl or chlorine, R7 is methyl, hydroxy, methoxy, acetoxy, fluorine, chlorine or bromine, Rb is methyl, ethyl or propyl, but at least one of the radicals R .., R3 or R4 must be a halogen atom,

   as well as their acid addition salts.



   According to the invention, these compounds are prepared by reacting a di. (- haloethyl) amine of the formula II
EMI1.2
 wherein Hal denotes a halogen atom, with a benzyl cyanide of the formula III
EMI1.3
  and subsequent Grignardation of the cyano compounds of the formula IV thus obtained
EMI2.1
 and hydrolysis of the ketimine compounds obtained into the keto compounds of the formula I.



   The ring closure occurs in the presence of a suitable condensing agent such as powdered sodium amide in an inert organic solvent, e.g. Toluene. The reaction temperature is generally between 40 and 2000C. The cyano compound of the formula IV is obtained in this way.



   A hydroxyl group present in a product of the formula I obtained according to the invention can optionally be methylated or acetylated. Conversely, it is also possible to demethylate a methoxy group on the phenyl ring or to saponify an acetyl group.



   If there is to be a hydroxyl group for the radical R7 in the end product, it is generally necessary to protect it by acylation or alkylation before the ring closure reaction begins. The deacylation of a hydroxyl group protected in this way takes place automatically during the hydrolysis of the ketimine compound. If there is a hydroxyl group protected by an alkyl radical on the phenyl ring of the cyano compound IV, it is advantageous to carry out the hydrolysis of the ketimine compound using hydrobromic or hydroiodic acid, since the alkyl radical is split off at the same time.



   If desired, a compound of the formula I can be converted into a physiologically acceptable acid addition salt, e.g. by treatment with an inorganic or organic acid, such as mineral acids. Acetic acid, methanesulfonic acid, tartaric acid, fumaric acid, maleic acid, citric acid, ascorbic acid, caproic acid or propionic acid.



   The new piperidine derivatives are distinguished by an extremely strong morphine-antagonistic effect: some of the compounds also have a pronounced analgesic effect. The new substances can therefore be used in human medicine as non-addictive analgesics or as additives to addictive analgesics, for example morphine, pethidine or ketobemidone. They can be processed into all forms of preparation customary for pharmaceutical purposes. For example, it can be used to make pills, coated tablets, tablets, suppositories, emulsions, solutions and injection solutions.



   Example trans-l 3-chloroallyl) -i (3-hydroxyphene. L) -4-cwetyl-piperidine hydrochloride
25 g (0.074 mol) of trans- 1- (3-chloroallyl) -4- (3-methoxyphenyl) -4.cyano.piperidine hydrochloride are shaken with 100 ml of water, 37 ml of 2N sodium hydroxide solution and 75 ml of benzene, the The benzene layer is separated off and the aqueous solution is extracted twice more with 75 ml of benzene each time. The benzene solutions are combined, dried with Na2SOg and the benzene evaporated in vacuo. The residue is dissolved in absolute benzene, the solution is again evaporated to dryness, the residue is redissolved in 50 ml of absolute benzene and this solution is added dropwise to a Grignard solution consisting of methyl magnesium iodide in benzene at 450C.

  Sufficient solvent is distilled off from the reaction mixture with stirring until the internal temperature has risen to 760 ° C. and the mixture is then stirred at this temperature for 16 hours. The reaction mixture is then poured onto 200 g of ice and 50 g of ammonium chloride and, after heating to 300 ° C., extracted three times with 200 ml of benzene each time. The combined benzene solutions are dried and the solvent evaporated. The residue that remains is ketimine, which is processed further without purification.



   After adding 50 g of phenol and 220 ml of 48% HBr, the mixture is refluxed for 4 hours, cooled, diluted with 220 ml of water and extracted twice with 100 ml of ether each time. The ether solutions are washed with 50 ml of water. The combined aqueous solutions are shaken out with 100 ml of ether and then evaporated to dryness in vacuo. A residue of 5 g remains, which crystallizes as the hydrochloride on dissolving in a little alcohol and acidifying with alcoholic HCl. The yield is 7.4 g (30.5% of theory) of F = 1840C (from ethanol / ether).



   The trans-N- (3-chloroallyl) - bis - (2-chloroethyl) -amine hydrochloride used as the starting substance can be obtained as follows: a) trans-N- (3-chloroallyl) -diethanolamine
36.8 g (0.35 mol) of diethanolamine, 42.5 g (0.385 mol) of trans-1,3-dichloropropene and 44 g (0.525 mol) of sodium bicarbonate are u in 43 ml of dimethylformamide. 107 ml of tetrahydrofuran boiled under reflux for 3 hours. The solvent is then evaporated in vacuo and the residue is shaken with 100 ml of water and 75 ml of chloroform.

  After separation in a separating funnel, the mixture is extracted several times with 50 ml of chloroform each time, the combined chloroform solutions are dried with Na2SO and, after the solvent has been distilled off, the compound is distilled in vacuo. After 6 g of first run, 55.5 g (88% of theory) of trans -N- (3-chloroallyl) diethanolamine with a boiling point of 0.4 = 134 to are obtained
1360C.

 

     b) trans-N- (3 -chloroallyl) -bis- (2-chloroethyl) -amine-hydro - chloride
46 g (0.256 mol) of trans-N- (3-chloroallyl) diethanolamine, partially dissolved in 50 ml of absolute chloroform, are added to 130 g within 30 minutes while cooling with ice and stirring
Thionyl chloride (1.1 mol) in 100 ml of chloroform was added.



  The mixture is then refluxed for 1 hour, cooled, and 300 ml of absolute ether are added. The hydrochloride of trans.N. (3-chloroallyl) bis (2-chloroethyl) amine which crystallizes on standing in the refrigerator is filtered off with suction and washed with ether. After drying in vacuo, 64 g (100% of theory) of the compound mentioned with an F = 620C (from alcohol / ether) are obtained.

 

Claims (1)

PATENTANSPRUCH PATENT CLAIM Verfahren zur Herstellung von Halogenallyl-pipendi nen der Formel I EMI3.1 worin Rl Wasserstoff oder Methyl, R2 Wasserstoff, Methyl, Chlor oder Brom, R3 Wasserstoff, Methyl, Fluor, Chlor oder Brom, R4 Wasserstoff, Methyl, Chlor oder Brom, R, Wasserstoff oder Methyl (a oder ,8), R6 Wasserstofff, Methyl oder Chlor, R7 Methyl, Hydroxy, Methoxy, Acetoxy, Fluor, Chlor oder Brom, R8 Methyl, Äthyl oder Propyl bedeuten, wobei jedoch mindestens einer der Reste R2, R: Process for the preparation of Halogenallyl-Pipendi NEN of the formula I. EMI3.1 where Rl is hydrogen or methyl, R2 is hydrogen, methyl, chlorine or bromine, R3 is hydrogen, methyl, fluorine, chlorine or bromine, R4 is hydrogen, methyl, chlorine or bromine, R is hydrogen or methyl (a or, 8), R6 is hydrogen, Methyl or chlorine, R7 denotes methyl, hydroxy, methoxy, acetoxy, fluorine, chlorine or bromine, R8 denotes methyl, ethyl or propyl, but at least one of the radicals R2, R: : oder R4 ein Halogenatom ist, dadurch gekennzeichnet, dass man ein Di-(p-halogenäthyl)-amin der Formel II EMI3.2 worin Hal ein Halogenatom bedeutet, mit Benzylcyanid der Formel III EMI3.3 umsetzt und anschliessend die Nitrilgruppe der so erhaltenen Cyanoverbindung der Formel IV EMI3.4 durch Grignardierung und Hydrolyse der intermediär erhaltenen Ketiminverbindung in die Ketogruppe überführt. : or R4 is a halogen atom, characterized in that a di (p-haloethyl) amine of the formula II EMI3.2 wherein Hal denotes a halogen atom, with benzyl cyanide of the formula III EMI3.3 reacts and then the nitrile group of the cyano compound of the formula IV obtained in this way EMI3.4 converted into the keto group by Grignardation and hydrolysis of the ketimine compound obtained as an intermediate. UNTERANSPRÜCHE 1. Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass man eine am Phenylring des Benzylcyanids vorhandene Hydroxylgruppe vor dem Ringschluss durch Alkylierung oder Acylierung schützt. SUBCLAIMS 1. The method according to claim, characterized in that a hydroxyl group present on the phenyl ring of the benzyl cyanide is protected from ring closure by alkylation or acylation. 2. Verfahren nach Patentanspruch, dadurch gekenn zeichnet, dass man das erhaltene Produkt in ein physiologisch annehmbares Säureadditionssalz überführt. 2. The method according to claim, characterized in that the product obtained is converted into a physiologically acceptable acid addition salt. C.H. Boehringer Sohn Vertreter: Brühwiler, Meier & Co., Zürich Anmerkung des Eidg. Amtes für geistiges Eigentumv Sollten Teile der Beschreibung mit der im Patentanspruch gegebenen Definition der Erfindung nicht in Einklang stehen, so sei daran erinnert, dass gemäss Art. 51 des Patentgesetzes der Patentanspruch für den sachlichen Geltungsbereich des Patentes massgebend ist. C.H. Boehringer son Representative: Brühwiler, Meier & Co., Zurich Note from the Federal Office for Intellectual Propertyv If parts of the description are not in accordance with the definition of the invention given in the patent claim, it should be remembered that according to Art. 51 of the Patent Act, the patent claim is decisive for the material scope of the patent.
CH1748267A 1964-01-24 1965-01-21 N-Allylpiperidine derivs. (I) R1 = H,Me R2 = H, Cl, Br, Me R3 = H, F, Cl, Br, Me R4 = H, Cl, Br, Me R5 = H, alpha- or beta - Me CH512469A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEB0075148 1964-01-24
DEB0075540 1964-02-21

Publications (1)

Publication Number Publication Date
CH512469A true CH512469A (en) 1971-09-15

Family

ID=25966942

Family Applications (3)

Application Number Title Priority Date Filing Date
CH1748267A CH512469A (en) 1964-01-24 1965-01-21 N-Allylpiperidine derivs. (I) R1 = H,Me R2 = H, Cl, Br, Me R3 = H, F, Cl, Br, Me R4 = H, Cl, Br, Me R5 = H, alpha- or beta - Me
CH86565A CH453358A (en) 1964-01-24 1965-01-21 Process for the preparation of new N-alkenyl-piperidines
CH1147671A CH512470A (en) 1964-01-24 1965-01-21 Process for the preparation of new haloallyl piperidines

Family Applications After (2)

Application Number Title Priority Date Filing Date
CH86565A CH453358A (en) 1964-01-24 1965-01-21 Process for the preparation of new N-alkenyl-piperidines
CH1147671A CH512470A (en) 1964-01-24 1965-01-21 Process for the preparation of new haloallyl piperidines

Country Status (8)

Country Link
BE (1) BE658583A (en)
CH (3) CH512469A (en)
DE (2) DE1445518A1 (en)
DK (3) DK118283B (en)
FR (2) FR1455818A (en)
GB (1) GB1076531A (en)
NL (1) NL6500808A (en)
SE (1) SE323370B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224188B1 (en) * 1999-10-20 2007-01-17 Archimedes Development Limited Nasal delivery composition comprising the methane sulphonate salt of morphine and chitosan

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH491918A (en) * 1968-01-11 1970-06-15 Geigy Ag J R Process for the preparation of new piperidine derivatives
CH492708A (en) * 1968-01-11 1970-06-30 Geigy Ag J R Process for the preparation of new piperidine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224188B1 (en) * 1999-10-20 2007-01-17 Archimedes Development Limited Nasal delivery composition comprising the methane sulphonate salt of morphine and chitosan

Also Published As

Publication number Publication date
DK121373B (en) 1971-10-11
BE658583A (en) 1965-07-20
DK118283B (en) 1970-08-03
GB1076531A (en) 1967-07-19
DK115392B (en) 1969-10-06
DE1445518A1 (en) 1968-12-05
SE323370B (en) 1970-05-04
FR1455818A (en) 1966-10-21
CH512470A (en) 1971-09-15
DE1445520A1 (en) 1968-12-12
CH453358A (en) 1968-06-14
NL6500808A (en) 1965-07-26
FR4317M (en) 1966-09-05

Similar Documents

Publication Publication Date Title
DE2111071B2 (en) 4- (1-Alkyl-4-piperidylidene) -4H-benzo [43] cyclohepta [1,2-b] thiophen-10 (9H) -ones or -9 (IOH) -ones, processes for their preparation and these Medicines containing compounds
CH512469A (en) N-Allylpiperidine derivs. (I) R1 = H,Me R2 = H, Cl, Br, Me R3 = H, F, Cl, Br, Me R4 = H, Cl, Br, Me R5 = H, alpha- or beta - Me
CH556837A (en) Spiro-indane-pyrrolidinyl-fluorobutyrophenone derivs - - analgesics and sedatives
DE1035150B (en) Process for the preparation of N-monosubstituted ª ‡ - (tert-aminoalkyl) -ª ‡ -phenyl acetamides
AT258291B (en) Process for the preparation of new haloalkenyl or alkenyl piperidines
DE673111C (en) Process for the preparation of amide-like offshoots of homologues of the isoxazole carboxylic acids
DE1568104A1 (en) Process for the preparation of tricyclic N-alkylated derivatives of acetamide
AT228790B (en) Process for the preparation of new 9-aminopropylidene-9,10-dihydroanthracenes and their acid addition salts
DE1643265C3 (en) Nuclear-substituted 2-aminomethylbenzhydrols, processes for their preparation and pharmaceuticals based on these compounds
AT318557B (en) Process for the preparation of new 2-exo-aminobornanes and their acid addition salts
DE1568253C (en) N substituted 1,2 diphenyl 2 acyloxy 3 amino methyl butenes
DE1126880B (en) Process for the preparation of piperazine derivatives
AT267075B (en) Process for the preparation of new 3- (dibenzo- [a, d] -1,4-cycloheptadien-5-yloxy) -nortropanes substituted on the nitrogen and of salts of these compounds
AT260930B (en) Process for the preparation of new 1- (2-Cycloalkylidenäthyl) piperidines, as well as their acid addition salts
AT269864B (en) Process for the preparation of new pyrrylaminoketone derivatives and their salts
DE951630C (en) Process for the preparation of 22-tertiary-aminobisnorcholanes unsaturated in the 20 (22) position
AT235836B (en) Process for the preparation of new basic substituted polymethylene tetrahydroquinolines
AT265245B (en) Process for the production of new basic esters and their salts
CH529756A (en) 4-benzoyl-4-hydroxy-3-phenyl-piperidine cpds - with hypolipaemic activity
DE2720915A1 (en) Antiulcer acylated 2-hydroxy-3-phenyl-1,3-di:amino-propane cpds. - prepd. e.g. by reacting the corresp non-acylated di:amine with reactive carboxylic acid deriv.
DE2264903A1 (en) PIPERIDINE DERIVATIVES
DE2642598A1 (en) NEW ISOINDOLINE DERIVATIVES, THEIR PRODUCTION AND COMPOSITIONS THEREOF
DE1568253B1 (en) N-substituted 1,2-diphenyl-2-acyloxy-3-aminomethyl-butenes
CH521306A (en) Tricyclic cpds antidepressive
CH564506A5 (en) Tricyclic cpds antidepressive

Legal Events

Date Code Title Description
PL Patent ceased